Company Thesis
Assertio Therapeutics (ASRT) is a specialty pharmaceuticals company which successfully divested itself of its painkiller exposure in response to the opioid crisis. Unfortunately, the company has zero growth catalysts within the next 3-5 years due to lack of scientific data backing up its pipeline candidates. There does exist an opportunity, however, for value investors as the stock is trading just above its free cash flow per share despite having no loss of exclusivity on its key products until 2022-2026. Without further ado, let's take a look as to why the company